Trial Tokenization to Understand the Long Term Effectiveness of a New COVID-19 Vaccine

An unnamed biopharma company running a Phase III COVID-19 vaccine trial needed to track infection rates and adverse events beyond the trial's observation period. It partnered with Datavant to tokenize trial participant data and connect it to real-world data sources, allowing long-term safety and effectiveness tracking without exposing personally identifiable information. The page describes this trial-tokenization approach conceptually but does not disclose specific trial results or numbers.

The customer is anonymised in Datavant’s own case study — not withheld by us.

Datavant is the tokenization and linkage infrastructure behind most of the US real-world-data ecosystem — it de-identifies and connects patient records across health-data partners without exposing PII.

This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.